Groundbreaking Progress in Sepsis Treatment: Grand Pharma's STC3141 Achieves Major Clinical Milestone Grand Pharma announces a significant advancement in sepsis treatment with STC3141, a drug that achieved major clinical endpoints in Phase II trials, aiming to fill critical gaps in therapy.

Groundbreaking Progress in Sepsis Treatment: Grand Pharma's STC3141 Achieves Major Clinical Milestone #China #Hong_Kong #Sepsis_Treatment #Grand_Pharma #STC3141